You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

187 search results for: symposium

Is Pediatric AD Linked to Other Allergic Diseases?
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
View more
Type 2 Inflammation Modulates the Neuroimmune Axis in PN
expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

Dermatology
Highlights from the WCD 2023 ADVENT symposium, examining how type 2 inflammation influences the neuroimmune axis in prurigo nodularis.
View more
AD and PN: Commonalities and Differences – A Case Study
expert video

AD and PN: Commonalities and Differences – A Case Study

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
Type 2 Inflammation Alters the Structure and Function of the Skin in AD
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
The Cumulative Disease Burden of AD in Adult Patients
expert video

The Cumulative Disease Burden of AD in Adult Patients

Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Eric Simpson discusses the array of allergic and non-allergic comorbidities that may impact adult patients with AD and how the cumulative burden of these comorbidities contributes to reduced quality of life. He goes on to discuss the potential for addressing the multimorbidities related to AD through early intervention before they have the opportunity to develop or progress.
View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
View more
The Benefits of Early Intervention in AD: More Than Skin Deep
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep

Dermatology
This video presentation of the full March 2024 ADVENT Atopic Dermatitis (AD) symposium, hosted in San Diego, California, features Dr. Eric Simpson, Dr. Katrina Abuabara, and Dr. Lawrence Eichenfield. The faculty present the latest information around the inflammatory processes in AD that promote a wide range of systemic and local effects, emphasizing the impact they have on patients’ quality of life. The faculty also discuss how these processes and burdens vary at specific life stages and may accumulate over time if left unchecked.
View more
UCARE 2023: CSU – The Brazil Perspective
expert video

UCARE 2023: CSU – The Brazil Perspective

Dermatology
Dr. Ensina guides discussions on the perspective of CSU management in Brazil.
View more
Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Dermatology
Highlights from the ESPD 2023 ADVENT symposium, exploring burden, skin barrier normalization, and current treatments for pediatric atopic dermatitis.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch
expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
View more
Skin Barrier Dysfunction in AD
expert video

Skin Barrier Dysfunction in AD

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region